A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT06510309 Phase 2 RECRUITING

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)

Details

Lead sponsor	Gottfried von Keudell, MD PhD
Phase	Phase 2
Status	RECRUITING
Enrolment	33
Start date	2026-02-11
Completion	2031-10-01

Conditions

• Lymphoma
• Marginal Zone Lymphoma
• MZL

Interventions

• Venetoclax
• Rituximab

Primary outcomes

• Complete Response Rate (CRR) — Up to 24 months
  Complete Response (CR) rate is defined as the proportion of participants achieving CR during study treatment. CR is defined based on RECIL criteria.

Countries

United States